RXST 240816 47.50P (RXST240816P47500) Stock Options, News & Quotes

US OptionsDetailed Quotes

RXST240816P47500

Watchlist

3.60
-0.30-7.69%

15min DelayClose Jul 23 15:59 ET

3.60High3.40Low

Intraday

5D
Daily

News

RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
Yahoo FinanceJul 22 16:05 ET
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
BenzingaJul 16 15:07 ET
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
Moomoo NewsJul 16 09:31 ET · Ratings
RxSight (RXST) Gets a Buy From Morgan Stanley
TipRanksJul 16 08:57 ET
RxSight Price Target Raised to $73.00/Share From $72.00 by BTIG
Dow JonesJul 15 13:06 ET
RxSight Is Maintained at Buy by BTIG
Dow JonesJul 15 13:06 ET

Comments

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US)$
$Vaxcyte(PCVX.US)$
$Legend Biotech(LEGN.US)$
$Janux Therapeutics(JANX.US)$
$Aerovate(AVTE.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Evolent Health(EVH.US)$
$NewAmsterdam Pharma(NAMS.US)$
$RxSight(RXST.US)$
$TYRA BIOSCIENCES, INC.(TYRA.US)$
$Edgewise Therapeutics(EWTX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Biogen(BIIB.US)$
$PepGen(PEPG.US)$
...

Moomoo AI

Feb 5 04:22

The recent insider sale of RxSight shares and the absence of insider purchases over the last year raise concerns about the company's outlook. Despite significant insider ownership, the lack of insider buying does not inspire confidence in the company's prospects.

Trade Alert: Independent Director Of RxSight William Link Has Sold Stock

Meticulous Trader

Jan 8 14:23

$RxSight(RXST.US)$ oww back in action now sold too early

Meticulous Trader

Dec 15, 2023 18:26

$RxSight(RXST.US)$ 213 % runs looks good here priming to jump 🔥

Meticulous Trader

Dec 14, 2023 12:38

$RxSight(RXST.US)$ bought few lets fo !